Dr. Sita Kugel receives $100K grant to study pancreatic neuroendocrine tumors

She will use preclinical models to study the role of DNA packaging in cancer development and metastasis
Dr. Sita Kugel
Dr. Sita Kugel Fred Hutch file photo

Dr. Sita Kugel of the Human Biology Division at Fred Hutchinson Cancer Research Center has received a one-year, $100,000 grant from the Neuroendocrine Tumor Research Foundation to study how a gene involved in modifying DNA may play a role in suppressing the development of pancreatic neuroendocrine tumors.

Tumors in the pancreas arise from two types of cells: exocrine cells, which make digestive enzymes, and endocrine cells, which make insulin. About 10 percent of pancreatic cancers begin as endocrine cells. Unfortunately, many patients with pancreatic neuroendocrine tumors, or PNETs,  are only diagnosed after the disease has begun to spread to other sites in the body. Patients need better treatments, particularly ones that tackle metastasis.

But there are few model systems of PNETs in which scientists can gain a deeper understanding of how PNETs develop, what drives the more metastatic version of the disease, and what molecules could serve as therapeutic targets.

“This has been a real bottleneck for research,” Kugel said.

But she has developed a preclinical model system that appears to align with many of the features of human PNETs. She works on a molecule called sirtuin 6, which helps keep DNA tightly packed and genes turned off. Kugel found that loss of SIRT6 in the pancreas, in conjunction with the loss of cell cycle checkpoint gene p53, triggered spontaneous, highly metastatic tumors of the organ’s endocrine cells.

Kugel has created an even more targeted preclinical model to study how SIRT6 may work to suppress metastasis of PNETs. She will also use the grant to look more closely at SIRT6 loss in human PNETs and compare her models to clinical reality. Kugel’s work in pancreatic ductal carcinomas has suggested that tumors that are low in SIRT6 are more sensitive to certain targeted therapies. Her studies of PNETs with low SIRT6 levels may reveal if these tumors have the same susceptibility.

“We want to understand how SIRT6 is suppressing both PNETs and PNET metastasis,” Kugel said. The goal is to understand the role of SIRT6 in PNET pathogenesis.

Read more about Fred Hutch achievements and accolades.

Sabrina Richards, a staff writer at Fred Hutchinson Cancer Center, has written about scientific research and the environment for The Scientist and OnEarth Magazine. She has a PhD in immunology from the University of Washington, an MA in journalism and an advanced certificate from the Science, Health and Environmental Reporting Program at New York University. Reach her at srichar2@fredhutch.org.

Related News

All news
Experimental drug makes some pancreatic cancers more vulnerable to chemo Early trial shows possibility of knocking down a ‘daunting’ cancer’s defense December 12, 2017
A new model for pancreatic cancer research: Flexible, precision-medicine trial 'driven by doing what is best for the individual patient' Flexible, precision-medicine trial ‘driven by doing what is best for the individual patient’ October 4, 2016
Internal pressure makes pancreatic tumors hard to treat The blood vessel-crushing, chemo-blocking pressure inside pancreatic tumors is almost entirely due to water trapped in gel form, study shows May 10, 2016

Help Us Eliminate Cancer

Every dollar counts. Please support lifesaving research today.